Home › Funds › LETKO, BROSSEAU & ASSOCIATES INC › MRNA

LETKO, BROSSEAU & ASSOCIATES INC position in MRNA

MODERNA INC · Health Care

LETKO, BROSSEAU & ASSOCIATES INC reported holding 724,830 shares of MRNA (MODERNA INC) in its Q2 2026 13F filing — a position valued at US$50.8M, representing 0.75% of its reported portfolio and ranking #45 among its reported holdings. LETKO, BROSSEAU & ASSOCIATES INC has disclosed MRNA holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)724.83K sh
Reported value held$50.76M
Portfolio Weight0.75%
First reportedQ4 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How LETKO, BROSSEAU & ASSOCIATES INC's MRNA position evolved

LETKO, BROSSEAU & ASSOCIATES INC first disclosed a stake in MRNA in Q4 2023 at 319,430 shares (US$31.8M). The position peaked in Q2 2026 at 724,830 shares, worth US$50.8M. Across 11 filings, LETKO, BROSSEAU & ASSOCIATES INC increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 724,830 shares valued at US$50.8M — a reduction of -23,985 shares quarter over quarter.. Notable position changes include a 62% increase in Q3 2024 (shares fell 38% over the following quarter), a 81% increase in Q4 2024 (shares fell 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 319.43K $31.77M New
Q1 2024 320.05K $34.10M Hold
Q2 2024 315.40K $37.45M Reduce
Q3 2024 511.14K $34.16M Add
Q4 2024 923.35K $38.39M Add
Q1 2025 896.42K $25.41M Reduce
Q2 2025 918.19K $25.33M Add
Q3 2025 913.39K $23.59M Reduce
Q4 2025 726.44K $21.42M Reduce
Q1 2026 748.82K $38.04M Add
Q2 2026 724.83K $50.76M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MRNA and 13F data

MRNA (MODERNA INC) is a Health Care company. 37 other funds we track also report a position in MRNA — the largest reported positions include Baillie Gifford & Co (US$1.28B), Theleme Partners LLP (US$564.3M), BANQUE PICTET & CIE SA (US$414.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MRNA

All MRNA fund holders →

FAQ

How long has LETKO, BROSSEAU & ASSOCIATES INC held MRNA?

LETKO, BROSSEAU & ASSOCIATES INC has disclosed MRNA holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is LETKO, BROSSEAU & ASSOCIATES INC's current position in MRNA?

As of Q2 2026, LETKO, BROSSEAU & ASSOCIATES INC holds 724.83K shares of MRNA (MODERNA INC), valued at $50.76M, representing 0.75% of its reported portfolio and ranking #45.

Has LETKO, BROSSEAU & ASSOCIATES INC been buying or selling MRNA?

In the latest 13F filing (Q2 2026), LETKO, BROSSEAU & ASSOCIATES INC reduced its position in MRNA. The position peaked in Q2 2026 at 724.83K shares.

Which other funds hold MRNA?

Other major institutional holders of MRNA include Baillie Gifford & Co, Theleme Partners LLP, BANQUE PICTET & CIE SA, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.